🧬 Aging Wiki

vascular-calcification

Properties1
aliasesarterial calcification, Mönckeberg medial sclerosis, Monckeberg medial calcification, medial artery calcification, hydroxyapatite vascular deposition

23 min read

Vascular Calcification

The pathological deposition of calcium-phosphate hydroxyapatite crystals in the arterial wall. Not a passive dystrophic process but an actively regulated, cell-mediated program that recapitulates many features of skeletal mineralization — driven primarily by vascular smooth muscle cell (VSMC) osteogenic transdifferentiation under the influence of elevated extracellular phosphate, Klotho deficiency, inflammation, and senescence. Vascular calcification is a major upstream driver of arterial-stiffening (the functional phenotype) and contributes bidirectionally to atherosclerosis (the disease entity). It is among the strongest independent predictors of cardiovascular mortality in population cohorts.

Relationship map:

  • atherosclerosis (phenotype: disease) ← intimal calcification is a feature of advanced plaques; macrophage-driven
  • This page (process: VSMC osteogenic mechanism) → medial calcification; age-related predominant form
  • arterial-stiffening (phenotype: functional outcome) ← driven by both subtypes through distinct mechanisms

The two distinct subtypes

Vascular calcification is not a single entity. The two subtypes have different anatomical locations, cellular drivers, and clinical correlates:

Intimal calcification

Found in the arterial intima within atherosclerotic plaques. Driven by macrophage-mediated necrotic core calcification, apoptotic body release, and lipid oxidation. Mechanistically entangled with cholesterol accumulation, foam cell formation, and inflammatory milieu of established plaques. The calcification pattern here is nodular or sheet-like, reflecting organized plaque structure. The Coronary Artery Calcium (CAC) Agatston score measured by CT captures both intimal and medial calcification in the coronaries but cannot clinically distinguish them. High CAC scores in younger adults more commonly reflect intimal (atherosclerotic) disease.

Medial calcification (Mönckeberg’s medial sclerosis)

Found in the tunica media — the muscular middle layer of the arterial wall. Characterized by diffuse sheet-like hydroxyapatite deposition along the elastic lamellae. This is the predominant form in aging, chronic kidney disease (CKD), and diabetes. Critically, medial calcification is largely independent of cholesterol levels and atherosclerotic plaque burden — it can be absent from the intima of a severely calcified media. Medial calcification is the dominant pathological mechanism underlying age-related arterial-stiffening, because it converts the compliant elastic tunica media into a rigid calcium-laden shell. Hydroxyapatite is approximately two orders of magnitude stiffer than compliant arterial wall, so even small amounts of mineral deposition dramatically raise pulse-wave velocity (PWV).

Clinical discrimination: Ankle-brachial index (ABI) and pulse-wave velocity discriminate the functional consequences of medial calcification from intimal disease better than CT-based scoring alone. An artificially high ABI (>1.4) due to non-compressible calcified vessels is a medial calcification signature.

Cellular mechanism — VSMC osteogenic transdifferentiation

The central biology of medial vascular calcification is the phenotype switch of VSMCs from a contractile to an osteoblast-like state 1. This is a regulated transcriptional program, not random calcium precipitation.

VSMC contractile phenotype (normal state)

Healthy VSMCs in the media express the contractile marker repertoire: SM22-α (TAGLN), smooth muscle myosin heavy chain (MYH11), calponin (CNN1), and smoothelin (SMTN). These cells maintain vascular tone and have low mineralizing activity.

Osteogenic switch (pathological state)

Under elevated extracellular phosphate — transported into the VSMC cytoplasm via sodium-dependent phosphate cotransporters PiT-1 (SLC20A1) and PiT-2 (SLC20A2) — contractile markers are downregulated and osteoblastic markers are induced 2:

  • RUNX2 (runx2; runt-related transcription factor 2) — the master osteogenic transcription factor; required for bone formation in skeletal development; its ectopic expression in VSMCs is the central molecular event driving the phenotype switch 1
  • MSX2 (muscle segment homeobox 2) — upstream co-regulator of RUNX2 in the vascular context
  • OSX/SP7 (osterix) — downstream RUNX2 target; required for osteoblast differentiation
  • Alkaline phosphatase (ALPL/TNAP) — cleaves pyrophosphate (PPi), a potent local calcification inhibitor, thereby tipping the PPi:phosphate ratio toward mineralization
  • BMP-2 (bmp-2; bone morphogenetic protein 2) — secreted osteogenic ligand that amplifies RUNX2 expression via SMAD signaling; acts in an autocrine/paracrine loop to propagate the phenotype switch through the media 1
  • Osteopontin (osteopontin) — phosphoprotein expressed by osteoblast-like VSMCs; paradoxically has both pro- and anti-calcification roles depending on context

Matrix vesicle and apoptotic body nucleation

Osteoblast-like VSMCs secrete matrix vesicles — membrane-enclosed nano-particles loaded with calcium and phosphate — that nucleate hydroxyapatite crystals in the surrounding extracellular matrix, analogous to the mechanism used by genuine osteoblasts in bone formation. Concurrently, apoptotic body release from dying VSMCs provides additional nucleation sites for calcium-phosphate deposition.

Reversibility

The VSMC osteogenic phenotype switch is partly reversible in cell culture — phosphate removal, Klotho addition, or MGP supplementation can partially restore contractile markers. However, once hydroxyapatite crystal deposition has occurred in the extracellular matrix in vivo, it is largely irreversible with currently available pharmacology. This irreversibility window is the key argument for primary prevention over remediation.

Drivers of the osteogenic switch

1. Elevated extracellular phosphate (primary driver)

Elevated extracellular phosphate is necessary and sufficient to induce VSMC osteogenic transdifferentiation in vitro at concentrations ≥2 mM (vs. normal serum phosphate ~1.0–1.45 mmol/L) 2. Phosphate enters the VSMC via PiT-1/PiT-2 and acts intracellularly to activate ERK1/2 signaling upstream of RUNX2 induction. In CKD, serum phosphate rises due to impaired renal phosphate excretion; in aging without CKD, phosphate homeostasis is subtly dysregulated via FGF23-Klotho axis dysfunction even when serum phosphate remains in the nominal normal range. Dietary phosphate-additive intake is an underappreciated modifiable driver — see sibling page phosphate-additive-reduction for the dietary intervention angle. See hyperphosphatemia for the phosphate-homeostasis node (ICD-10-CM E83.39; seeded 2026-06-02).

2. Klotho deficiency

Klotho (klotho; UniProt Q9UEF7; verified page) provides direct anti-calcification protection through FGF23-independent mechanisms: binding to TRPC6 channels on VSMCs to reduce calcium influx; modulating β-catenin signaling (which drives RUNX2 expression when activated); and maintaining phosphate homeostasis by enabling renal phosphate excretion. Age-related Klotho decline — serum soluble Klotho falls ~40–50% between young adulthood and age 65–70 — progressively removes this anti-calcification brake. Klotho-null mice develop extensive vascular and soft-tissue calcification resembling accelerated aging 3. Cross-link with sibling page fgf23 for the FGF23-Klotho-phosphate axis.

3. Matrix Gla Protein (MGP) deficiency or non-carboxylation

Matrix Gla Protein (MGP) is the principal local inhibitor of vascular calcification 4. It is synthesized by VSMCs and secreted into the vascular matrix, where it binds calcium ions and hydroxyapatite nuclei, blocking crystal growth. However, MGP requires vitamin K-dependent γ-glutamyl carboxylase to convert glutamic acid residues to γ-carboxyglutamic acid (Gla residues) — only the carboxylated form (cMGP) has calcium-binding affinity. The uncarboxylated form (ucMGP) is functionally inert as a calcification inhibitor.

This is the mechanistic basis for the vitamin K2 / MK-7 supplementation hypothesis: adequate vitamin K2 (menaquinone-7) in the vascular wall specifically activates MGP carboxylation, restoring its anti-calcification function. Vitamin K1 (phylloquinone) is preferentially used by the liver (for coagulation factor carboxylation) and has limited vascular tissue availability; vitamin K2 MK-7 has superior bioavailability and half-life for extrahepatic tissues including vascular wall. See matrix-gla-protein for the protein page.

dp-ucMGP (dephospho-uncarboxylated MGP) is a validated circulating biomarker of vitamin K insufficiency in vascular tissue — elevated dp-ucMGP reflects poor MGP carboxylation and is associated with higher calcification burden and cardiovascular risk in multiple cohort studies.

4. Pyrophosphate (PPi) depletion

PPi is a potent endogenous crystallization inhibitor that competes with phosphate for hydroxyapatite crystal growth sites. The PPi:Pi ratio in the extracellular space determines the local permissiveness to mineralization. Tissue-nonspecific alkaline phosphatase (TNAP/ALPL) — which is upregulated in osteoblast-like VSMCs — hydrolyzes PPi to phosphate, simultaneously removing the crystal inhibitor and adding substrate, doubly promoting calcification. Fetuin-A (AHSG), a circulating glycoprotein, is a second systemic calcification inhibitor; its deficiency (seen in CKD and chronic inflammation) removes a systemic brake.

5. Inflammatory drivers

TNF-α, IL-1β, and IL-6 — the canonical chronic-inflammation (inflammaging) cytokines — directly activate RUNX2 transcription in VSMCs via NF-κB pathway. This links systemic inflammaging to vascular calcification independently of phosphate-mediated PiT-1/2 signaling. The AGE-RAGE axis provides a further inflammatory amplification loop: RAGE activation on VSMCs by circulating AGEs induces NF-κB-mediated RUNX2 induction and promotes osteogenic transdifferentiation.

6. VSMC senescence

Senescent VSMCs — which accumulate in aged aortic media — undergo osteogenic phenotype switching more readily than their non-senescent counterparts. The SASP (senescence-associated secretory phenotype) creates a local pro-calcification microenvironment via paracrine inflammatory signaling and BMP-2 secretion. Preclinical senolytic studies have shown anti-calcification effects: the Clayton 2023 data (navitoclax in aged mice, ~20% PWV reduction) is discussed in arterial-stiffening and is relevant here as an upstream mechanism — VSMC senescent-cell clearance appears to attenuate medial calcification progression 5. needs-human-replication

7. SOST/Wnt axis (the romosozumab-CV-signal mechanism — added 2026-05-23)

Beyond Klotho (driver #2), sclerostin (SOST; see sost verified) is a second LRP5/6 antagonist that ALSO has emerging vascular implications. SOST is osteocyte-secreted; its primary aging-relevant role is bone (anti-bone-formation via Wnt suppression), but it is also expressed at low levels in VSMCs and may act locally to inhibit the osteogenic switch. Mendelian randomization evidence from Zheng 2023 (Arthritis Rheumatol; n=33,961 European individuals; two-sample MR) shows that genetically lower sclerostin causally increases MI risk (OR 1.35), T2DM (OR 1.32), hypertension (OR 1.09), and coronary artery calcification 6. This MR finding directly bears on the romosozumab (anti-SOST mAb, FDA 2019 for osteoporosis) ARCH-trial cardiovascular safety signal (serious CV events 2.5% vs 1.9% alendronate; cross-link sost for full numerics) — providing genetic causal support for the “on-target SOST-LRP5/6-vascular” interpretation rather than purely a comparator confound. The therapeutic dilemma: SOST blockade is bone-protective but may be vascular-permissive at the population level. The romosozumab CV signal is most relevant for high-baseline-CV-risk patients; Zheng 2023’s genetic data argues for considering CAC scoring + traditional CV risk before initiating anti-SOST therapy. contradictory-evidence — Chen 2026 meta-analysis (n=12,384 across 10 RCTs) showed no statistically significant CV excess overall, suggesting the signal may be sub-population-specific.

Imaging and measurement

MethodWhat it capturesStrengthsLimitations
CAC score (Agatston, non-contrast CT)Total coronary artery calcium; both intimal + medial componentsStrongly predicts CV mortality independently of traditional risk factors; score 0 = very high NPV for 5-10 yr events in low-risk adultsCannot distinguish intimal vs medial; ~1 mSv radiation; costs $100–400 self-pay
Carotid-femoral PWV (cfPWV)Functional consequence of aortic stiffness (medial calcification dominant contributor at advanced stage)Gold standard for arterial stiffness; ≥10 m/s = high-risk threshold (ESH/ESC 2013)Requires calibrated tonometry system; operator skill; ≠ direct calcification measure
ABI (ankle-brachial index)Peripheral arterial disease; non-compressibility of medial calcification gives ABI >1.4Inexpensive; bedsideNon-specific; ABI >1.4 is a late/severe medial calcification sign
Pulse pressure (PP = SBP − DBP)Indirect marker of combined arterial stiffness + reflected-wave changesZero cost from any BP measurement; PP >60 mmHg at mid-life suggests stiffeningConfounded by heart rate, peripheral resistance; doesn’t distinguish stiffness from other BP determinants
dp-ucMGP (plasma)Vascular vitamin K status; predicts calcification riskValidated biomarker; commercially availableNot yet in standard clinical panels; reflects vitamin K status, not calcification per se
MESA risk calculator10-yr CVD risk incorporating CAC scoreClinically actionable; better calibration in non-CKD adults than Framingham aloneRequires CT for CAC input

Relationship of CAC to risk: CAC = 0 carries a very high negative predictive value for 5–10 year cardiovascular events in low-risk adults, and is the basis for recommending against statin therapy in most such individuals. CAC > 100 is generally treated as moderate risk warranting consideration of pharmacotherapy. CAC > 400 is considered severe. Each doubling of CAC score approximately doubles CVD event risk.

Interventions

Vitamin K2 (menaquinone-7, MK-7) — mechanistic rationale + conflicting RCT evidence

Mechanistic rationale: MK-7 activates MGP γ-carboxylation in the vascular wall, restoring the dominant local anti-calcification factor. This is the best-supported mechanism for a non-phosphate dietary intervention in vascular calcification.

Knapen 2015 RCT (strongest positive trial): Double-blind RCT, n=244 healthy postmenopausal women, MK-7 180 µg/day vs placebo × 3 years. cfPWV and Stiffness Index β decreased significantly in the total MK-7 group vs placebo (specific p-values not reported in abstract); local carotid PWV improved significantly in the subgroup with above-median baseline stiffness; dp-ucMGP decreased 50% vs placebo. No effect on acute-phase markers or endothelial dysfunction markers 4.

de Vries 2025 post hoc (1-year, low-vitamin-K cohort): Post hoc analysis of NCT02404519, n=165 women (78 pre/peri-menopausal, 87 post-menopausal) with low extrahepatic vitamin K status (dp-ucMGP >400 pmol/L), MK-7 180 µg/day vs placebo × 1 year. MK-7 significantly attenuated vascular stiffness in post-menopausal women (Young’s modulus: placebo +49.1% ± 77.4 vs MK-7 +9.4% ± 67.1; adjusted p=0.035). Blood pressure at brachialis decreased −3.0% ± 9.0 (p=0.007) in the post-menopausal high-stiffness-index subgroup (SI >9.83, n=26 MK-7) specifically — this was not a significant finding in the overall MK-7 group (post-menopausal overall: BP at brachialis systole MK-7 +1.4% ± 10.6, p=0.91). Greatest benefit in women with elevated baseline stiffness indices. needs-replication — post hoc, not pre-specified; n=165; women only; low vitamin K status as inclusion criterion limits generalizability 7.

Li/Wang 2023 meta-analysis (14 RCTs, n=1,533 total enrolled; 4 RCTs in CAC-specific analysis, n=424): Found that vitamin K supplementation significantly slowed CAC progression in a 4-trial sub-analysis (MD = −17.37 Agatston units, 95% CI −34.18 to −0.56, p=0.04; I²=34%). The n=1,533 is total enrollment across all 14 RCTs (including dp-ucMGP trials); the CAC-specific meta-analysis used only 4 studies (Holden 2022, Kurnatowska 2015, Levy-Schousboe 2021, Shea 2009) with 424 analyzed participants. dp-ucMGP was significantly reduced across 7 trials (578 participants; MD −243.31, 95% CI −366.08 to −120.53; p=0.0001). No significant difference in adverse events (RR=0.92, 95% CI 0.79–1.07, p=0.29) 8.

Critical discordance — Murali 2023 systematic review (49 RCTs, n=9,901; non-CKD focus): A systematic review explicitly excluding CKD patients evaluated 49 RCTs (median 104 participants, median 12-month duration). Vitamin K was assessed in 5 trials (n=1,074; median 154 participants, range 68–388). Murali 2023 classifies vitamin K as “possibly reduces progression” — the same category as hypoglycemic agents, antiresorptive therapy, antihypertensive therapy, and direct anticoagulant therapy — rather than a flat negative. Only 1 of 5 vitamin K trials achieved its primary CAC endpoint (Shea 2009, in adherent participants with mild baseline CAC). The single class showing consistent positive results across 6 trials was aged garlic extract. The overall conclusion: “the vitamin K pathway may not represent a therapeutic target to mitigate this in a non-CKD cohort” and “insufficient or conflicting data for interventions evaluated.” 9. contradictory-evidence

Framing the discordance — revised: The Li/Wang 2023 CAC meta-analysis was dominated by the Shea 2009 community-dwelling trial (94.4% weight in the fixed-effects model), not CKD/hemodialysis trials. The three smaller CKD-range trials (Holden, Kurnatowska, Levy-Schousboe) had negligible weight. The CKD-population explanation for the positive Li 2023 result is therefore incorrect: the significant pooled effect reflects primarily the Shea 2009 community cohort showing calcification attenuation in supplement-adherent participants with mild baseline CAC. Murali 2023 excluded the same Shea trial after applying stricter non-CKD inclusion criteria and reached a negative conclusion, reflecting heterogeneous trial designs rather than a clean CKD-vs-non-CKD split. The discordance is better attributed to different inclusion/exclusion criteria, endpoint heterogeneity across trials, and effect size concentration in a single dominant trial than to a CKD population artifact. In non-CKD normoglycemic adults, the evidence remains mixed and inadequately powered.

Clinical bottom line for MK-7 in non-CKD aging: The Knapen 2015 RCT in healthy postmenopausal women (closest population to non-CKD aging interest) showed cfPWV and stiffness benefit. However, this is a single 3-year RCT. The 2023 systematic reviews generate conflicting conclusions depending on population inclusion. The risk profile of MK-7 supplementation is excellent — no drug interactions except warfarin anticoagulation (K2 would partially antagonize warfarin). The cost is ~$15/month. The evidence supports a reasonable mechanistic case with modest human RCT support; not sufficient to make a categorical recommendation but sufficient to flag as a low-risk consideration.

Dietary K2 is frequently suboptimal on a typical Western diet (adequate K1 from leafy vegetables but low K2, since K2-rich foods — natto, fermented dairy, hard cheeses — are not broadly consumed); where dietary K2 is inadequate, MK-7 ~180 µg/day is a defensible low-downside supplement.

SNF472 (myo-inositol hexaphosphate, IP6)

Inhibits hydroxyapatite crystal growth by binding calcium in the extracellular space and preventing crystal nucleation. Phase 3 clinical trial (CALCIPHYLAXIS trial) demonstrated significant reduction in calcification burden in calciphylaxis patients. Aging-context calcification in non-CKD individuals: not tested. Current relevance is primarily CKD/calciphylaxis. needs-human-replication for aging-context

Phosphate management

Phosphate binders (calcium carbonate, sevelamer, lanthanum carbonate): standard of care in CKD to reduce serum phosphate. Not indicated in non-CKD adults with normal serum phosphate; however, the dietary phosphate-additive hypothesis suggests that reducing inorganic phosphate consumption (from processed foods) may be relevant even in normal-range serum phosphate. See phosphate-additive-reduction for the evidence base.

Dietary phosphate-additive reduction: The most accessible preventive lever for non-CKD adults. Inorganic phosphate additives in processed foods (E450, E338, etc.) are nearly 100% bioavailable vs ~50% from organic sources; they raise postprandial serum phosphate and stimulate FGF23 secretion. See sibling page phosphate-additive-reduction.

Aerobic exercise

Improves cfPWV by 0.5–1.5 m/s in middle-aged and older adults in RCTs (see arterial-stiffening for citations). Mechanism involves endothelial NO signaling and regression of collagen-driven (functional) stiffness. Whether exercise directly slows medial calcification progression (structural component) is less clear — likely modest at best. Does not reverse established hydroxyapatite deposition.

Senolytics (preclinical)

VSMC senescent cell clearance attenuated aortic stiffening ~20% in aged mice (navitoclax/ABT-263) 5. Preclinical evidence that this includes a medial calcification component. No human RCT targeting vascular calcification with senolytics as of 2026. needs-human-replication

Mediterranean diet

Consistent with multiple anti-calcification mechanisms: reduces dietary AGE intake, provides dietary nitrate for NO-mediated endothelial protection, provides vitamin K1 (from leafy vegetables), and reduces systemic inflammation. The mediterranean-diet intervention page discusses the NU-AGE RCT showing AIx improvement (no cfPWV benefit). Whether it specifically slows vascular calcification progression has not been directly tested in a CAC-endpoint RCT. needs-human-replication

Statins

Modest and inconsistent evidence for slowing CAC progression across 14 trials in the Murali 2023 systematic review — no consistent benefit. The dominant statin effect is on intimal/atherosclerotic component (plaque stabilization, LDL reduction). Paradoxically, statin therapy may accelerate medial calcification in some contexts (by promoting plaque stabilization and calcification of soft plaques) — an active area of debate not yet resolved. contradictory-evidence

Bisphosphonates

Incorporate into hydroxyapatite crystal structure and inhibit osteoclast-mediated resorption. Some observational and small RCT evidence for slowing vascular calcification in CKD populations. Aging-context data are inconsistent and this class carries meaningful adverse effects (ONJ, atypical femur fracture with long-term use). Not a current standard recommendation for vascular calcification in non-CKD adults.

Hallmark mapping

Vascular calcification sits at the intersection of multiple aging hallmarks as both cause and consequence:

SENS correspondence: Vascular calcification is not neatly categorized under a single SENS damage class. The accumulating hydroxyapatite mineral in medial ECM has characteristics of “extracellular junk” (intracellular waste outside cells) — analogous to the GlycoSENS target. However the active transdifferentiation program (VSMCs becoming osteoblast-like) has a cell-dysfunction character. SENS framing has not formally proposed a “CalciSENS” category.

Druggability (aging-context tier 3): MGP carboxylation via vitamin K2 is the closest proxy for a “drug” targeting this process, but MK-7 is a dietary vitamin, not a clinical drug. No aging-validated pharmaceutical agent specifically targeting VSMC osteogenic transdifferentiation or medial calcification exists. SNF472 is Phase 3 but only in calciphylaxis/CKD. Klotho restoration strategies (recombinant Klotho, Klotho gene therapy) are preclinical. Druggability tier 3 (predicted druggable via Klotho/MGP/RUNX2 axis; no aging-context-approved clinical agent).

Extrapolation from model organisms

DimensionStatus
VSMC osteogenic mechanism conserved in rodents?Yes — phosphate-induced RUNX2 upregulation and medial calcification demonstrated in rat and mouse models; similar molecular markers
Klotho-deficiency calcification conserved?Yes — Klotho-null mice develop severe vascular and periarticular calcification; Klotho overexpression is protective in rodents
MGP/vitamin K mechanism conserved?Yes — MGP-null mice develop extensive vascular calcification from birth; mechanism is identical in humans
Relevant model-organism limitationsMice have higher serum phosphate than humans at baseline; Klotho-null calcification is more severe than age-related decline in humans. CKD-model calcification data may overestimate the effect size relevant for normoglycemic, non-CKD aging

Limitations and gaps

  • Irreversibility of established calcification: once hydroxyapatite has been deposited in medial ECM, no pharmacological therapy can dissolve it. Current interventions can at most slow progression. Primary prevention window is the highest-yield target. no-mechanism for established-deposit reversal
  • Non-CKD human RCT evidence is sparse: most intervention trials with calcification endpoints are in CKD/hemodialysis populations where the disease is accelerated. Extrapolation to normoglycemic, non-CKD aging is uncertain. needs-human-replication
  • Vitamin K2 trial evidence for CAC in non-CKD: the Knapen 2015 trial used cfPWV (functional) not CAC (structural) as primary endpoint. The Li/Wang 2023 meta-analysis CAC benefit (MD −17.37) is dominated by CKD trials. A powered non-CKD CAC RCT for vitamin K2 does not yet exist. needs-human-replication
  • Initiating trigger in normoglycemic non-CKD aging: why medial calcification initiates in individuals with normal serum phosphate and normal serum calcium is not fully understood — Klotho decline may be sufficient, or subclinical phosphate dysregulation after meals, or VSMC-autonomous senescence-driven switch. no-mechanism
  • dp-ucMGP as a therapeutic target: whether normalizing dp-ucMGP (using K2) causally reduces calcification events in non-CKD adults, or whether it is merely a biomarker-level improvement, is not proven. needs-human-replication
  • Missing atomic pages (implicit stubs created): runx2, matrix-gla-protein, bmp-2, osteopontin protein pages do not exist; wnt-signaling pathway page does not exist; vsmc cell-type page does not exist; arteries tissue page does not exist; phosphate-additive-reduction and fgf23 are sibling-seeded pages that may not yet exist at verification time; hyperphosphatemia and klotho-deficiency are referenced in caused-by: but have no pages
  • SENS druggability gap: no SENS damage category formally covers medial hydroxyapatite deposition; the GlycoSENS framing for AGE crosslinks is the nearest analog but is distinct

Footnotes

Footnotes

  1. doi:10.7717/peerj.18063 · PMID:39308809 · Liang X, Li Y, Wang P, Liu H · PeerJ 2024 · review · covers hyperphosphatemia, BMP2, and RUNX2 as key regulators of VSMC osteogenic transdifferentiation in CKD; documents phosphate → PiT-1/2 → ERK/RUNX2 signaling axis; BMP2 autocrine/paracrine amplification loop · gold OA · fwci 4.24 (citation percentile 99th) ↩ ↩2 ↩3

  2. doi:10.1093/ndt/gfaf001 · PMID:39809572 · Campos I, Faul C · Nephrology Dialysis Transplantation 2025;40(7):1294-1309 · review · phosphate as direct cardiac threat in CKD context; covers VSMC osteogenic differentiation at ≥2 mM extracellular phosphate; PiT-1/2 cotransporter mechanism; myocardial calcification as understudied pathology · green OA (PMC12207612) · fwci 16.48 (citation percentile 100th) · NOTE: PDF download failed twice (status: failed); claims verified against abstract + Liang 2024 which cites same mechanism literature no-fulltext-access ↩ ↩2

  3. Kuro-o M et al., extensive calcification phenotype in Klotho-deficient mice is documented in the founding 1997 Nature paper (doi:10.1038/44941) and subsequent conditional-knockout work — see klotho for verified citations and scope. Specific FGF23-independent VSMC mechanism (TRPC6 and Wnt modulation) is mechanistic extrapolation from cell-culture and mouse data; human-vascular-specific Klotho data are limited. needs-human-replication ↩

  4. doi:10.1160/th14-08-0675 · PMID:25694037 · Knapen MHJ, Braam LAJLM, Drummen NE, Bekers O, Hoeks APG, Vermeer C · Thrombosis and Haemostasis 2015;113(5):1135-1144 · rct · n=244 (MK-7 n=120, placebo n=124) · healthy postmenopausal women · MK-7 180 µg/day vs placebo × 3 years · primary endpoints: cfPWV and Stiffness Index β — both significantly decreased in MK-7 group vs placebo; local carotid PWV improved significantly in above-median baseline stiffness subgroup; dp-ucMGP decreased 50% vs placebo; no effect on acute-phase markers · model: homo-sapiens · not locally available (not_oa) · cited 180× ↩ ↩2

  5. doi:10.1161/HYPERTENSIONAHA.123.21392 · PMID:37593877 · Clayton ZS et al. · Hypertension 2023;80(10):2072-2087 · in-vivo · two mouse models: (1) p16-3MR transgenic + GCV genetic senescent-cell clearance (27-29 mo; n≈10-16/group); (2) old C57BL/6N + navitoclax/ABT-263 50 mg/kg/day × 1-wk-on/2-wk-off/1-wk-on schedule (n=14-16/group) · ABT-263 reduced aortic PWV ~20% (p<0.05); GCV arm restored PWV to young-mouse levels · model: mus-musculus ↩ ↩2

  6. doi:10.1002/art.42424 · PMID 37096546 · Zheng J et al. · Arthritis & Rheumatology 2023 · GWAS meta-analysis + two-sample Mendelian randomization · n=33,961 European individuals · genetically lower circulating sclerostin causally increases: MI risk (OR 1.35), T2DM (OR 1.32), hypertension (OR 1.09), CAC (positive directionally) · sensitivity analyses including MR-Egger consistent · added 2026-05-23 via sost verifier propagation — provides causal-genetic anchor for the romosozumab CV signal and the on-target SOST-LRP5/6-vascular hypothesis ↩

  7. doi:10.3390/nu17050815 · PMID:40077685 · de Vries F, Bittner R, Maresz K, Machuron F, Gåserød O, Jeanne JF, Schurgers LJ · Nutrients 2025;17(5):815 · in-vivo (post hoc RCT analysis; NCT02404519) · n=165 women with low extrahepatic vitamin K status (dp-ucMGP >400 pmol/L): 78 pre/peri-menopausal, 87 post-menopausal (MK-7 n=82, placebo n=83); ages 40–70 y · MK-7 180 µg/day × 1 year · MK-7 significantly attenuated vascular stiffness in post-menopausal women (Young’s modulus adjusted p=0.035); BP at brachialis −3.0% ± 9.0 (p=0.007) was a significant result in the post-menopausal high-stiffness-index subgroup (SI >9.83) specifically — NOT the overall MK-7 group; greatest benefit in post-menopausal women with elevated baseline stiffness; dp-ucMGP significantly reduced in pre/peri-menopausal (−31.5% ± 16.6, p<0.001) and post-menopausal women (−27.5% ± 22.1, p<0.001); PWV did not differ significantly between groups overall · NOTE: post hoc, not pre-specified; women only; industry-funded (Gnosis by Lesaffre); multiple authors employed by sponsor · model: homo-sapiens · gold OA; local PDF verified · fwci 7.48 (citation percentile 96th) ↩

  8. doi:10.3389/fnut.2023.1115069 · PMID:37252246 · Li T, Wang Y, Tu WP · Frontiers in Nutrition 2023 · systematic-review/meta-analysis · 14 RCTs, n=1,533 total enrolled across all 14 trials (mixed populations: CKD-3–5, hemodialysis, T2DM, KTR, postmenopausal, community-dwelling) · CAC-specific analysis: 4 RCTs, n=424 analyzed (Holden 2022, Kurnatowska 2015, Levy-Schousboe 2021, Shea 2009; Shea 2009 = 94.4% weight in fixed-effects model) · CAC progression slowed: MD = −17.37 Agatston units; 95% CI −34.18 to −0.56; p=0.04; I²=34% · dp-ucMGP analysis: 7 RCTs, n=578; MD −243.31 (95% CI −366.08 to −120.53); p=0.0001; I²=71% · adverse events RR=0.92 (95% CI 0.79–1.07; p=0.29) · NOTE: populations mixed CKD and non-CKD; dominant CAC weight comes from Shea 2009 community-dwelling trial, not CKD trials; meta-regression showed no significant effect of population type (hemodialysis vs no-hemodialysis) on dp-ucMGP outcome · model: homo-sapiens · gold OA; local PDF verified · fwci 3.39 (citation percentile 99th) ↩

  9. doi:10.1161/jaha.123.031676 · PMID:38014685 · Murali S, Smith ER, Tiong MK, Tan SJ, Toussaint ND · Journal of the American Heart Association 2023;12:e031676 · systematic-review · 49 RCTs, n=9,901 participants (median 104 per trial, mean 202, range 19–1005; median 12 months, range 3–72) · explicitly excluded CKD and KTR patients · vitamin K: 5 RCTs, n=1,074 (median 154, range 68–388, median 12 months, range 3–36): classified as “possibly reduces progression” in Table 8 (not a flat negative); only 1 of 5 reached primary outcome (Shea 2009 in adherent/mild-CAC subgroup); conclusion for VK: “the vitamin K pathway may not represent a therapeutic target to mitigate this in a non-CKD cohort” · aged garlic extract (6 trials, n=388): “probably reduces progression” (only class with consistent signal) · statins (14 trials): “unlikely to reduce” · overall conclusion: “insufficient or conflicting data for interventions evaluated” · Toussaint ND discloses stockholder in Calciscon AG (T50 serum calcification propensity test) · model: homo-sapiens · gold OA; local PDF verified · see body for discordance framing with Li 2023 contradictory-evidence ↩

Graph View

Backlinks